Targeted Drug Dramatically Lowers Lung Cancer Recurrence Risk

A new study presented at ASCO and published in the New England Journal of Medicine reveals that the targeted drug selpercatinib significantly reduces lung cancer recurrence risk by 83%. This benefit applies to patients with a rare genetic subtype of the disease. Co-led by UCLA Health investigators, this finding marks a major advancement in treating this specific form of lung cancer.